DK563487D0 - Stabil farmaceutisk komposition af rekombinant beta-interferon - Google Patents

Stabil farmaceutisk komposition af rekombinant beta-interferon

Info

Publication number
DK563487D0
DK563487D0 DK563487A DK563487A DK563487D0 DK 563487 D0 DK563487 D0 DK 563487D0 DK 563487 A DK563487 A DK 563487A DK 563487 A DK563487 A DK 563487A DK 563487 D0 DK563487 D0 DK 563487D0
Authority
DK
Denmark
Prior art keywords
stable pharmaceutical
pharmaceutical composition
beta interferon
recombinant beta
ionic polymeric
Prior art date
Application number
DK563487A
Other languages
English (en)
Other versions
DK563487A (da
Inventor
Ze Ev Shaked
Tracy Stewart
Jody Thomson
James William Thomson
Terrance Taforo
Susan Hershenson
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of DK563487D0 publication Critical patent/DK563487D0/da
Publication of DK563487A publication Critical patent/DK563487A/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK563487A 1986-10-27 1987-10-27 Stabil farmaceutisk komposition af rekombinant beta-interferon DK563487A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92342386A 1986-10-27 1986-10-27

Publications (2)

Publication Number Publication Date
DK563487D0 true DK563487D0 (da) 1987-10-27
DK563487A DK563487A (da) 1988-04-28

Family

ID=25448670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK563487A DK563487A (da) 1986-10-27 1987-10-27 Stabil farmaceutisk komposition af rekombinant beta-interferon

Country Status (9)

Country Link
EP (1) EP0270799B1 (da)
JP (1) JPS63179833A (da)
AT (1) ATE111744T1 (da)
AU (2) AU8019187A (da)
CA (1) CA1294215C (da)
DE (1) DE3750574T2 (da)
DK (1) DK563487A (da)
FI (1) FI95002C (da)
NO (1) NO175704C (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
US4961969A (en) * 1987-05-11 1990-10-09 Cetus Corporation Process for recovering microbially produced interferon-β
US5151265A (en) * 1987-11-03 1992-09-29 Genentech, Inc. Gamma interferon formulation
US5004605A (en) * 1987-12-10 1991-04-02 Cetus Corporation Low pH pharmaceutical compositions of recombinant β-interferon
IL89662A (en) * 1989-03-19 1997-11-20 Interpharm Lab Ltd Kiryat Weiz Pharmaceutical compositions comprising interferon-beta
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US20030171292A1 (en) 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
CA2147466A1 (en) * 1992-10-20 1994-04-28 Just P. J. Brakenhoff Interleukin-6 receptor antagonists
CA2185162A1 (en) 1994-03-07 1995-09-14 Robert F. Halenback (Deceased) Compositions for the inhibition of tnf formation and uses thereof
IT1272252B (it) 1994-05-16 1997-06-16 Applied Research Systems Formulazioni liquide di interferone beta
US5556771A (en) * 1995-02-10 1996-09-17 Gen-Probe Incorporated Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification
GB9506051D0 (en) * 1995-03-24 1995-05-10 Univ Singapore Gene expression
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DK1017413T4 (da) 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins
US7544354B2 (en) 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
HU228583B1 (en) 2000-11-07 2013-04-29 Novartis Vaccines & Diagnostic Stabilized interferon compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
BR0213292A (pt) 2001-10-15 2006-05-23 Chiron Corp tratamento de pneumonia severa por administração de inibidor da via de fator tecidual (tfpi)
EP2248830A1 (en) 2003-11-04 2010-11-10 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
PL1684805T3 (pl) 2003-11-04 2010-12-31 Novartis Vaccines & Diagnostics Inc Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
PL1682177T3 (pl) 2003-11-04 2011-03-31 Novartis Vaccines & Diagnostics Inc Zastosowanie antagonistycznych przeciwciał anty-CD40 do leczenia przewlekłej białaczki limfocytowej
PT1680141E (pt) 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40
JP4810431B2 (ja) 2003-11-04 2011-11-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｂ細胞に関連する癌に対する治療方法
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
EP3338798A1 (en) 2011-01-06 2018-06-27 Bionor Immuno AS Multimeric peptide
IN2014KN02769A (da) 2012-06-06 2015-05-08 Bionor Immuno As
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
KR102279717B1 (ko) 2013-04-23 2021-07-20 세다르스-신나이 메디칼 센터 형광단들로부터의 가시 광 이미지 및 적외선 광 이미지를 동시에 레코딩하기 위한 시스템들 및 방법들
JP6608370B2 (ja) 2014-01-17 2019-11-20 シーダーズ―シナイ メディカル センター 受容体標的化構築物およびその使用
US10029997B2 (en) 2014-06-12 2018-07-24 Cedars-Sinai Medical Center Compositions and methods for treating cancers
CN107072951A (zh) 2014-07-22 2017-08-18 雷莫内克斯生物制药有限公司 用于递送生物活性物质或蛋白质的组合物及其用途
EP3215186A4 (en) 2014-11-04 2018-10-24 University of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
EP3292139B1 (en) 2015-05-05 2020-10-28 The Regents of The University of California H3.3 ctl peptides and uses thereof
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
US11567078B2 (en) 2015-08-31 2023-01-31 Cedars-Sinai Medical Center Blood cell biomarker for late onset Alzheimer's disease
KR20180103816A (ko) 2016-02-09 2018-09-19 오토텔릭 엘엘씨 췌장암을 치료하기 위한 조성물과 방법
KR101843985B1 (ko) 2016-02-09 2018-03-30 오토텔릭 엘엘씨 암을 치료하기 위한 조성물과 방법
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and use thereof
BR112019016281A2 (pt) 2017-02-06 2020-04-14 Lemonex Inc veículo de substância fisiologicamente ativa
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
US20210121493A1 (en) 2017-07-25 2021-04-29 Cedars-Sinai Medical Center Methods for treating liver diseases
JP7293194B2 (ja) 2017-08-22 2023-06-19 シーダーズ－サイナイ・メディカル・センター 癌治療のための組成物および方法
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
KR102658659B1 (ko) * 2018-04-19 2024-04-17 에르테에스 로만 테라피-시스테메 아게 인터페론 적용을 위한 마이크로니들 시스템
US11690799B2 (en) 2018-04-19 2023-07-04 Lts Lohmann Therapie-Systeme Ag Microneedle system for applying interferon
AU2019374905A1 (en) 2018-11-08 2021-06-10 Cedars-Sinai Medical Center Use of clazakizumab to desensitize and improve renal transplantation in HLA-sensitized patients
US20220073605A1 (en) 2018-12-20 2022-03-10 Cedars-Sinai Medical Center Clazakizumab in the treatment of chronic antibody-mediated rejection of organ transplant
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55102519A (en) * 1979-01-31 1980-08-05 Green Cross Corp:The Stabilization of interferon
CA1190148A (en) * 1981-10-13 1985-07-09 Samuel S. Asculai Interferon-containing compositions
JPS5910524A (ja) * 1982-07-08 1984-01-20 Toray Ind Inc インタ−フエロン組成物およびその製造法
US4992271A (en) * 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
EP0107498B1 (en) * 1982-10-25 1990-05-16 Genentech, Inc. Synergistic human interferon activity
EP0150067A3 (en) * 1984-01-23 1986-12-30 Takeda Chemical Industries, Ltd. Stable composition of gamma-interferon
US4680175A (en) * 1984-02-07 1987-07-14 Interferon Sciences, Inc. Interferon administration vehicles
US4606917A (en) * 1984-10-03 1986-08-19 Syntex (U.S.A) Inc. Synergistic antiviral composition
JPS61277633A (ja) * 1985-05-31 1986-12-08 Toray Ind Inc インタ−フエロン組成物

Also Published As

Publication number Publication date
EP0270799A1 (en) 1988-06-15
NO874445D0 (no) 1987-10-26
AU1063392A (en) 1992-03-19
NO175704B (no) 1994-08-15
DE3750574D1 (de) 1994-10-27
AU659127B2 (en) 1995-05-11
EP0270799B1 (en) 1994-09-21
FI874706A (fi) 1988-04-28
CA1294215C (en) 1992-01-14
JPS63179833A (ja) 1988-07-23
FI95002C (fi) 1995-12-11
FI874706A0 (fi) 1987-10-26
DE3750574T2 (de) 1995-02-02
NO175704C (no) 1994-11-23
AU8019187A (en) 1988-04-28
ATE111744T1 (de) 1994-10-15
FI95002B (fi) 1995-08-31
NO874445L (no) 1988-04-28
DK563487A (da) 1988-04-28

Similar Documents

Publication Publication Date Title
DK563487A (da) Stabil farmaceutisk komposition af rekombinant beta-interferon
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
KR100656125B1 (ko) 장기 안정화 제제
KR970706017A (ko) 안정한 알파 인터페론 수용액 제형(Stable, aqueous alfainterfer on solution for mulations)
ATE106247T1 (de) Formulierung für rekombinantes beta-interferon, verfahren zur gewinnung und stabilisierung des beta-interferons und dessen verwendung.
DE3681243D1 (de) Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.
EP0374257B1 (en) STABLE INTERFERON $g(b) COMPOSITION
DK97987A (da) Solubilisering af proteiner til farmaceutiske sam mensaetninger under anvendelse af polymerkonjugation
DK1381432T3 (da) HSA-frie interferon-beta-præparater
EE05201B1 (et) Glkoslitud interferoon-beeta, selle kasutamine ja seda sisaldav farmatseutiline kompositsioon, meetod interferoon-beeta-1a aktiivsuse pikendamiseks ja leiutisekohase valgu valmistamiseks
NL930119I2 (nl) Farmaceutische en veterinaire preparaten van cysteine-125-verminderde muteïnen van interleukine-2 ende produktie daarvan.
DE68924491D1 (de) Intrascheidenabgabe von aktiven Polypeptiden.
DE69518152D1 (de) Flüssige beta-interferon formulierungen
DK0496973T3 (da) Porcine somatotropiner med ændringer i alfa-helix 1 regionen og kombinationer med andre mutationer.
ES2142840T3 (es) Proteina que se une al interferon alfa/beta, su preparacion y las composiciones farmaceuticas que la contienen.
FI822331A0 (fi) Blandningar foer lokal anvaendning pao huden
DK0456153T3 (da) Galeniske vandige formuleringer af erythopoietin og deres anvendelse

Legal Events

Date Code Title Description
ATS Application withdrawn